The last 5 years has seen a dramatic evolution in treatments for multiple myeloma. Previously, bortezemib, lenalidomide and pomalidamide, in combination with steroids and used sequentially, was the mainstay of treatment for transplant ineligible patients. With the introduction of carfilzomib, panobinostat, elotuzumab, daratumumab and ixazomib as add-ons to existing therapies, there is now a much large number of possible combinations and sequences.